Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection... ORIGINAL ARTICLE An International Interpretation Study Using the ALK IHC  Antibody D5F3 and a Sensitive Detection Kit Demonstrates  High Concordance between ALK IHC and ALK FISH and  between Evaluators Murry W. Wynes, PhD,* Lynette M. Sholl, MD,† Manfred Dietel, MD,‡ Ed Schuuring, PhD,§ Ming S. Tsao, MD, FRCPC,‖ Yasushi Yatabe, ME, PhD,¶ Raymond R. Tubbs, DO,# and Fred R. Hirsch, MD, PhD***†† score. IHC negativity was scored by seven of seven and six of seven Introduction: The goal of personalized medicine is to treat patients evaluators on three and two FISH-positive cases, respectively. IHC with a therapy predicted to be efficacious based on the molecular positivity was scored on two FISH-negative cases by seven of seven characteristics of the tumor, thereby sparing the patient futile or toxic readers. There was agreement among seven of seven and six of seven therapy. Anaplastic lymphoma kinase (ALK) inhibitors are effective readers on 88% and 96% of the cases before review, respectively, and against ALK-positive non–small-cell lung cancer (NSCLC) tumors, after review there was agreement among seven of seven and six of but to date the only approved companion diagnostic is a break-apart seven on 95% and 97% of the cases, respectively. fluorescence in situ hybridization (FISH) assay. Immunohistochemistry Conclusions: On the basis of expert evaluation the ALK IHC test (IHC) is a clinically applicable cost-effective http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK

Journal of Thoracic Oncology , Volume 9 (5) – May 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/an-international-interpretation-study-using-the-alk-ihc-antibody-d5f3-s6EoATKnJX

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864

Abstract

ORIGINAL ARTICLE An International Interpretation Study Using the ALK IHC  Antibody D5F3 and a Sensitive Detection Kit Demonstrates  High Concordance between ALK IHC and ALK FISH and  between Evaluators Murry W. Wynes, PhD,* Lynette M. Sholl, MD,† Manfred Dietel, MD,‡ Ed Schuuring, PhD,§ Ming S. Tsao, MD, FRCPC,‖ Yasushi Yatabe, ME, PhD,¶ Raymond R. Tubbs, DO,# and Fred R. Hirsch, MD, PhD***†† score. IHC negativity was scored by seven of seven and six of seven Introduction: The goal of personalized medicine is to treat patients evaluators on three and two FISH-positive cases, respectively. IHC with a therapy predicted to be efficacious based on the molecular positivity was scored on two FISH-negative cases by seven of seven characteristics of the tumor, thereby sparing the patient futile or toxic readers. There was agreement among seven of seven and six of seven therapy. Anaplastic lymphoma kinase (ALK) inhibitors are effective readers on 88% and 96% of the cases before review, respectively, and against ALK-positive non–small-cell lung cancer (NSCLC) tumors, after review there was agreement among seven of seven and six of but to date the only approved companion diagnostic is a break-apart seven on 95% and 97% of the cases, respectively. fluorescence in situ hybridization (FISH) assay. Immunohistochemistry Conclusions: On the basis of expert evaluation the ALK IHC test (IHC) is a clinically applicable cost-effective

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: May 1, 2014

There are no references for this article.